The Future of Psychedelic Research Is In Limbo — Why the FDA’s Decision Changed Everything The FDA just rejected MDMA-assisted therapy for PTSD. What's next for psychedelic drugs in science and everyday life? Inverse · Aug 17, 2024
FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. It is the first such decision issued on a psychedelic drug application. The Conversation · Aug 12, 2024